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iabetes carries a high risk of athero-
sclerosis, and cardiovascular dis-
ease, especially coronary heart
disease (CHD) and stroke, is by far the
leading cause of death among patients
with type 2 diabetes. Although statins re-
duce the risk of major vascular events by
about one-ﬁfth per millimole per liter re-
duction in LDL cholesterol, with similar
proportional reductions in major coro-
nary events, stroke, and the need for cor-
onary revascularization, the residual risk
remains high. In the Scandinavian Simva-
statin Survival Study (4S) (1), although
the relative risk reduction in diabetic pa-
tients was larger than in nondiabetic
patients, simvastatin-treated diabetic pa-
tients were still at higher risk of death
than the placebo-treated nondiabetic
patients. Multifactorial intervention re-
ducestheriskevenfurther,butsigniﬁcant
danger remains. Current guidelines call
for an aggressive treatment strategy to re-
duce LDL cholesterol, blood pressure,
andglucoselevelsindiabeticpatients,but
data concerning the management of high
triglyceride(TG)levelsandlowHDLcho-
lesterol levels remains inconclusive. This
article reviews the data concerning dia-
betic dyslipidemia and its management.
DIABETIC DYSLIPIDEMIA — The
cluster of lipid abnormalities associated
with type 2 diabetes is deﬁned by a high
concentration of TG and small dense LDL
and a low concentration of HDL choles-
terol. Plasma LDL cholesterol levels are
generally normal. Insulin resistance is be-
lieved to contribute to this atherogenic
dyslipidemiabyincreasingthehepaticse-
cretionofVLDLandotherapolipoprotein
(apo)B-containing lipoprotein particles,
as a result of increased free fatty acid ﬂux
to the liver (2,3). This may also be the
result of a diminished suppressive effect
of insulin on apoB secretion, either at the
level of the regulation of apoB degrada-
tion, or inhibition of microsomal TG
transfer protein activity (4). Through the
action of cholesterol ester transfer pro-
tein, TGs are transferred from VLDL to
HDL, creating TG-rich HDL particles,
which are hydrolyzed by hepatic lipase
and rapidly cleared from plasma (5). A
similarcholesterolesterprotein-mediated
transfer of TGs from VLDL to LDL con-
tributes to the formation of small dense
LDL particles (6). Other mechanisms, in-
cluding impaired clearance of lipid and
lipoproteins may also be involved.
TRIGLYCERIDES, HDL
CHOLESTEROL, AND
CARDIOVASCULAR RISK— The
question whether hypertriglyceridemia
causescoronaryarterydisease(CAD)oris
simply a marker for the accompanying li-
poprotein abnormalities (especially low
HDL cholesterol levels and small dense
LDL particles) is still controversial. In a
meta-analysis of 17 population-based
prospective studies, increased plasma TG
levels were associated with increased cor-
onary disease risk in both men and
women, after adjustment for HDL choles-
terol and other risk factors (7). A direct
atherogenic effect of TG-rich particles,
particularly intermediate-density li-
poprotein, and remnant particles has
been presumed. In a more recent meta-
analysis, adjustment for established coro-
nary risk factors, especially HDL
cholesterol, substantially attenuated the
magnitude of risk associated with high
TG levels, leaving an odds ratio of about
1.7 in individuals with TG levels in the
top third of the population, compared
with those in the bottom third (8).
Two recent studies shed light on the
roleofnonfastingTGlevelsasariskfactor
for cardiovascular disease. In the Wom-
en’s Health Study (9), adjustment for lev-
els of total and HDL cholesterol, and
measures of insulin resistance (diabetes,
BMI, and C-reactive protein), weakened
the association between TG levels and the
riskofcardiovascularevents,leavinglittle
independent relationship with cardiovas-
cular events. In contrast, nonfasting TG
levels were associated with incident car-
diovascular events, independent of tradi-
tional risk factors, levels of other lipids,
and markers of insulin resistance (9). In
the Copenhagen City Heart Study (10),
nonfastingTGlevelswereassociatedwith
increased risk of myocardial infarction,
ischemicheartdisease,anddeathafterad-
justment for age, total cholesterol, BMI,
hypertension, diabetes, smoking, alcohol
consumption, physical inactivity, lipid-
loweringtherapy,postmenopausalstatus,
and hormone therapy in women (10).
The levels of nonfasting TG were highly
correlated with those of remnant lipopro-
tein cholesterol (10). These results may
also reﬂect the effect of postprandial hy-
pertriglyceridemia (independent of and
cumulativetotheeffectofhyperglycemia)
on endothelial function.
The association between reduced
HDL cholesterol levels and increased risk
ofheartdiseaseis,ontheotherhand,well
established, independently of TG levels
and other risk factors (11). In fact, the
“low HDL cholesterol” or “hypoalpha”
syndrome is the most frequent lipopro-
tein abnormality in coronary patients
(12). Intravascular ultrasound studies
demonstrate that patients with low HDL
cholesterol and high TG levels have more
extensive coronary atheromas than those
with an isolated elevation of LDL choles-
terol (13). Patients with reduced HDL
cholesterol levels show intima-media
thickness results similar to those with fa-
milial hypercholesterolemia (14), while a
high level of HDL cholesterol reduced
plaque growth in subjects with preexist-
ing carotid atherosclerosis (15).
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moval of cholesterol from cells, including
those in atherosclerotic plaques, and
carry them to the liver, but the mecha-
nisms by which HDL confer protection
from atherosclerosis include more than
just reverse cholesterol transport. HDL
particles seem to have anti-inﬂammatory
and antioxidant properties, inhibiting the
oxidation of LDL cholesterol and the ex-
pression of cellular adhesion molecules
and monocyte recruitment. The HDL
may also reduce the risk of thrombosis
by inhibiting platelet activation and
aggregation.
Recent studies, however, demon-
strated that it may be the level of apoA-I,
rather than the level of HDL cholesterol,
that is important in reducing the risk of
atherosclerosis (16). In fact, high plasma
HDL cholesterol and large HDL particles
may be associated with increased CAD
risk when levels of apoA-I and apoB re-
main constant. In contrast, apoA-I re-
mains negatively associated with CAD
risk, even in high concentrations.
DO WE NEED DRUGS TO
REDUCE TG AND/OR
INCREASE HDL
CHOLESTEROL
LEVELS?— Statins are potent in re-
ducing LDL cholesterol levels and CAD
risk, and statin therapy in patients with
lowerHDLcholesterollevelsreducescor-
onary risk to approximately that of pa-
tients with higher HDL cholesterol levels
on placebo. But even statins fail to elimi-
nate most of the risk, especially in sub-
jects at high risk, such as diabetic
patients.IntheCollaborativeAtorvastatin
Diabetes Study (CARDS), treatment of di-
abetic patients with atorvastatin (10 mg/
day for 3.9 years) reduced the risk for
major cardiovascular events by approxi-
mately one-third (17), leaving two-thirds
of the risk unaffected. In the Treating-to-
New-Targets (TNT) study, signiﬁcantly
more patients with metabolic syndrome
thanthosewithouthadamajorcardiovas-
cular event, irrespective of statin treat-
ment (18).
A post hoc analysis of the TNT study
demonstrated that the HDL cholesterol
levelwaspredictiveofmajorcardiovascu-
lareventsalsoinpatientsreceivingstatins
(19). Even among statin-treated subjects
who achieved LDL cholesterol levels be-
low 70 mg/dl, the subjects in the highest
quintile of HDL cholesterol levels were at
less risk for major cardiovascular events
than those in the lowest quintile.
Inaposthocanalysisoffourprospec-
tive randomized intravascular ultrasound
trials, a decrease in LDL cholesterol levels
and an increase in HDL cholesterol levels
were independent predictors of atheroma
regression (20). Statin therapy was asso-
ciatedwithregressionofcoronaryathero-
sclerosis when LDL cholesterol was
substantially reduced, and HDL choles-
terol was increased by 7.5% (20).
Similar results were found regarding
TG levels in statin-treated patients. In the
Pravastatin or Atorvastatin Evaluation
andInfectionTherapy(PROVE-IT)study,
low on-treatment TG (150 mg/dl) was
associated with reduced CHD risk, com-
paredwithhigherTG,independentofthe
level of LDL cholesterol (21). For each 10
mg/dl decrement in on-treatment TG, the
incidence of major coronary events was
lower by 1.4% after adjustment for LDL
cholesterol or non-HDL cholesterol and
other covariates (19). The combination of
low LDL cholesterol (70 mg/dl), low C-
reactive protein (2 mg/l), and low TG
(150 mg/dl) was associated with the
lowest event rates.
However,althoughstatinscanreduce
LDL cholesterol levels by as much as 50%
or more, their effect on HDL cholesterol
levels is modest, at best. These data dem-
onstrate the need for TG-reducing and/or
HDLcholesterol–elevatingtherapywitha
proven efﬁcacy in terms of reducing mor-
bidity and mortality.
CURRENT THERAPIES
AIMED AT REDUCING TG
AND INCREASING HDL
CHOLESTEROL LEVELS
Peroxisome proliferator–activated
receptor- agonists
Fibrates are among the oldest agents used
to treat patients with lipid disorders, but
even after more than 5 decades of use,
their role in preventing CAD is still
disputed.
Activation of peroxisome prolifera-
tor–activated receptor (PPAR)- has
numerous effects that lead to an improve-
ment in dyslipidemia. These include the
inductionofenzymesmediatingfattyacid
oxidation,stimulationoflipidimportinto
thecellinpartbyinductionoflipoprotein
lipase, and suppression of apoC-III,
whichinterfereswiththeclearanceofTG-
containinglipoproteins.Theresultisare-
duction of TG levels, increase in HDL
cholesterol levels, and reduction of small
dense LDL levels. These changes have a
favorable effect on endothelial function
and hemorrheologic parameters. Fibrates
also increase adiponectin levels and may
reduce the incidence, or delay the onset,
of diabetes in patients with impaired fast-
ing glucose.
However,dataontheeffectofﬁbrates
on markers of inﬂammation, cell adhe-
sion, and oxidation are controversial: in
one study, fenoﬁbrate did not reduce
plasma levels of C-reactive protein, solu-
ble intercellular adhesion molecule-1 (sI-
CAM)-1, vascular cell adhesion molecule-1
(sVCAM-1), matrix metalloproteinase-9
(MMP-9), secretory phospholipase A2
(sPLA2),andoxidizedLDL(22),whereasin
other studies, PPAR- activation decreased
levels of endothelin-1, tissue factor, and
VCAM-1 (23) and cytokine release (24).
In the Diabetes Atherosclerosis Inter-
ventionStudy(DAIS),fenoﬁbratetherapy
was associated with less angiographic
progression of atherosclerotic lesions in
diabetic patients without known coro-
nary disease. This effect seemed to be me-
diated, at least in part, by changes in LDL
particle size (25).
In the Veterans Affairs High-Density
Lipoprotein Intervention Trial (VA-HIT),
treatment with gemﬁbrozil in men with
CHD, an HDL cholesterol level of 40
mg/dl (mean 32 mg/dl), and a TG level of
300 mg/dl (mean 160 mg/dl) resulted
in a 22% reduction in the relative risk for
nonfatal myocardial infarction or death
from coronary causes. The risk was re-
ducedby34%inpatientswithdiabetesor
a high fasting plasma insulin level (26).
Post hoc analyses from other studies
have demonstrated the efﬁcacy of ﬁbrates
inpreventingcardiovasculareventsinpa-
tients with diabetes or metabolic dyslipi-
demia. In the Helsinki Heart Study,
treatment with gemﬁbrozil resulted in a
71% lower incidence of CHD events in
the subgroup of patients free of CHD at
baseline, with the LDL cholesterol/HDL
cholesterol ratio above 5 and TG level
200 mg/dl (27). In the Bezaﬁbrate In-
farction Prevention (BIP) study, although
bezaﬁbrate had no effect on all-cause and
cardiac mortality in the entire study pop-
ulation, it was associated with a 31% rel-
ative reduction in the risk of myocardial
infarction in patients with the metabolic
syndrome (28).
The largest trial designed to test the
efﬁcacy of ﬁbrates in preventing morbid-
ity and mortality was the Fenoﬁbrate
Intervention and Event Lowering in Dia-
betes (FIELD) trial (29). In this trial, fe-
noﬁbrate failed to signiﬁcantly reduce the
risk of the primary outcome of coronary
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ing include a higher than expected rate of
patientsreceivingstatins,alowerthanex-
pectedincreaseinHDLcholesterollevels,
and unfavorable nonlipid effects, includ-
ing increases in the levels of homocys-
teine, creatinine, and hemoglobin A1C
(29). The effect of fenoﬁbrate on lipopro-
teinparticlesubclassesalsoseemedsome-
what unfavorable: while there was an
increase in LDL particle size, HDL2 was
decreased, and small dense HDL3 in-
creased, with no effect on apoA-I levels.
Effortsofdevelopingmorepotentand
selective PPAR- agonists have met with
safety concerns, including an increase in
LDL cholesterol and creatinine levels.
Because virtually all diabetic patients
should receive statins, and the effects of
statins and ﬁbrates may be complemen-
tary, the combination of statins and ﬁ-
brates is of great interest. Clinical studies
with ﬁbrate-statin combinations have
shown superior lipid-modifying efﬁcacy
compared with statin monotherapy in re-
ducing TG, VLDL cholesterol, non-HDL
cholesterol,andLDLcholesterollevels,as
well as raising HDL cholesterol levels. A
greatereffectinreducingsmalldenseLDL
levels, as well as markers of inﬂammation
(C-reactive protein and lipoprotein–
associated phospholipase A2) (30), was
alsofound.Althoughtherearesafetycon-
cerns, no cases of rhabdomyolysis were
reported in about 1,000 patients who re-
ceivedfenoﬁbrateplusstatinintheFIELD
study (29). The lipid-lowering arm of the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study, involving
about5,500patientswithtype2diabetes,
iscomparingtheeffectofsimvastatinplus
fenoﬁbrate to simvastatin alone on car-
diovascularmorbidityandmortality(30).
Data from ACCORD are expected in
2009.
Niacin
Niacin monotherapy or in combination
with other agents was in clinical use dur-
ing the late 1970s and 1980s, but lipid-
lowering treatments shifted largely to
statins.RecentfailuresindevelopingHDL
cholesterol–raising drugs have rekindled
interest in this drug. High-dose niacin
(1–3 g) decreases VLDL, increases HDL,
and has a modest effect on LDL. Among
lipid-modifying agents, niacin is the most
potent agent currently available to increase
HDL cholesterol and the only one that re-
duces lipoprotein(a) concentrations.
Much of VLDL production is con-
trolled by the provision of fatty acids to
the liver. Niacin is thought to decrease
circulatingfattyacidsbyinhibitingthere-
lease of fatty acids in adipose tissue medi-
ated by hormone-sensitive lipase. The
underlying mechanism is unknown, but
recent data suggest that an orphan G pro-
tein–coupled receptor may be the nico-
tinic acid receptor and mediate the
antilipolytic effects of this vitamin.
In the Coronary Drug Project, niacin
reduced mortality among myocardial in-
farction survivors, although, contrary to
the relatively rapid effect of statins, mor-
tality rates were almost identical through-
out the ﬁrst 68 months of follow-up and
did not begin to diverge until month 72
(31). In the HDL-Atherosclerosis Treat-
ment Study (HATS), the combination of
niacin and simvastatin was associated
with regression of atherosclerosis, as as-
sessedbycoronaryangiography(32).The
simvastatin-niacin combination was also
associated with a 90% reduction in the
composite end point of major cardiovas-
cular events (32). In the Arterial Biology
for the Investigation of the Treatment Ef-
fects of Reducing Cholesterol-2 (ARBI-
TER-2) study, the addition of niacin to
statin therapy slowed the progression of
atherosclerosis as assessed by intima-
media thickness among individuals with
known CHD and moderately low HDL
cholesterol (33). In addition to the bene-
ﬁcial effects on intima-media thickness
progression, a large, although statistically
nonsigniﬁcant, reduction in recurrent
CHD events was also noted (33).
Although there are concerns regard-
ing the effect of niacin on the control of
diabetes, most studies demonstrated that
niacin therapy has only a minor effect on
glucose levels in diabetic patients.
Allstudiesexaminingtheeffectsofni-
acin on morbidity and mortality were rel-
atively small-scale. Two large clinical
outcomestudies,theTreatmentofHDLto
Reduce the Incidence of Vascular Events
(HPS2-THRIVE)andtheAtherothrombo-
sis Intervention in Metabolic Syndrome
with Low HDL/High Triglycerides and
Impact on Global Health Outcomes
(AIM-HIGH) studies are under way and
expected to shed more light on the role of
niacin.
-3 fatty acids
-3 fatty acids have beneﬁcial effects in
lowering TG levels, especially in the post-
prandial state, including in patients with
atherogenic dyslipidemia associated with
the metabolic syndrome and diabetes.
The mechanism through which -3
fatty acids exert their effect is not entirely
understood. They are converted into a
wide variety of bioactive eicosanoids and
act as ligands for several nuclear tran-
scriptionfactors,therebyalteringgeneex-
pression. Other proposed beneﬁcial
effectsof-3fattyacidsincludeeffectson
arrhythmia, platelet aggregation, inﬂam-
mation, endothelial function, and blood
pressure.
Anumberofsmallstudieshaveinves-
tigated the combination of a statin and
-3 fatty acids as therapy in patients with
mixeddyslipidemia.Inonestudy,thead-
ditionof-3fattyacidstosimvastatinsig-
niﬁcantly decreased TG, VLDL, and non-
HDL cholesterol levels compared with
simvastatin alone (34). In obese insulin-
resistant men with dyslipidemia, consis-
tent with the metabolic syndrome, the
combination of -3 fatty acids and ator-
vastatin decreased VLDL-apoB secretion
and increased the fractional catabolic rate
ofVLDL-apoBandconversionofVLDLto
LDL (35). In another study, the combina-
tion of atorvastatin -3 fatty acids in-
creased HDL2 levels, thereby correcting
the functional defect in HDL characteris-
tic of the metabolic syndrome (36).
The data on clinical efﬁcacy of -3
fattyacidsintermsofmorbidityandmor-
tality is still controversial. Three large tri-
als—Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infartio miocardico
(GISSI)-Prevenzione (GISSI-Prevenzi-
one) (37), Japan EPA Lipid Intervention
Study (JELIS) (38), and GISSI-heart fail-
ure (39)—have shown clinical outcome
beneﬁts of dietary supplementation with
-3 fatty acids, but a recent systematic
review did not demonstrate a clear effect
on total mortality, or combined cardio-
vascular events (40). However, it should
be noted that patients in these trials were
not dyslipidemic, and the dose of -3
fatty acids used did not produce any sig-
niﬁcantchangeintheleveloftriglycerides
or HDL cholesterol. The ORIGIN study
(Outcome Reduction with an Initial
GlargineIntervention)islookingtodeter-
minewhether-3acidethylestersreduce
cardiovascular death compared with a
placeboin12,000patientswithdysgly-
cemia (41).
FUTURE PROSPECTS— The con-
cept of cholesterol ester transfer protein
(CETP) inhibition suffered a serious blow
whentheresultsoftheILLUMINATEtrial
demonstrated an increase in adverse
events in patients treated with torcetrapib
(42). However, because the increase in
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target effects of torcetrapib, studies with
other CETP inhibitors such as anac-
etrapib and JTT-705 are under way and
will help to shed light on this question
(43).
Another therapeutic approach em-
phasizes the role of apoA-I in the anti-
atherogenic function of HDL particles. In
one small study, intravenous recombi-
nant apoA-I Milano/phospholipid com-
plexes produced regression of coronary
atherosclerosis as measured by intravas-
cular ultrasound (44). ApoA-I mimetic
peptides are being investigated and, at
least in animal models, were found to in-
crease the formation of pre- HDL, im-
prove HDL-mediated cholesterol efﬂux,
increase paraoxonase activity, and con-
vert HDL from proinﬂammatory to anti-
inﬂammatory (45).
Large unilamellar vesicles have been
developed to serve as “sink or sponge”
binding cholesterol from HDL, thus re-
generating HDL particles able to take up
cholesterol from peripheral tissues (46).
Finally, liver X receptor agonists are
also investigated as a possible measure of
increasing reverse cholesterol transport
and reversing atherosclerosis (47). How-
ever, the ﬁrst generation of nonselective
LXR and LXR agonists increased
plasma TG levels, and a search for an
LXR-speciﬁc agonist, which may be free
of that effect, is under way.
All of these therapies are in the pre-
liminary stages of development, and it
will be some time before large-scale clin-
ical trials are conducted.
CONCLUSIONS — The risk of car-
diovascular morbidity and mortality in
diabetic patients remains high, despite
modern effective therapies, such as st-
atins. Some of the risk may be attributed
to other components of the metabolic
dyslipidemia, namely high TG level, low
HDL cholesterol level, and small dense
LDL. Current attempts at controlling this
form of dyslipidemia have ended with ei-
ther conﬂicting or entirely disappointing
results. We are in dire need of additional
therapeutic options for these high-risk
patients. Ongoing trials with currently
available therapies are expected to pro-
vide some much-needed answers, and
new therapies are eagerly expected.
Acknowledgments— No potential conﬂicts
of interest relevant to this article were
reported.
References
1. Scandinavian Simvastatin Survival Study
Group. Cholesterol lowering with simva-
statin improves prognosis of diabetic pa-
tients with coronary heart disease: a
subgroup analysis of the Scandinavian
Simvastatin Survival Study (4S). Diabetes
Care 1997;20:614–620
2. Krauss RM, Siri PW. Dyslipidemia in type
2diabetes.MedClinNAm2004;88:897–
909
3. Laws A, Hoen HM, Selby JV, Saad MF,
Haffner SM, Howard BV. Differences in
insulinsuppressionoffreefattyacidlevels
by gender and glucose tolerance status:
relation to plasma triglyceride and apoli-
poproteinBconcentrations:InsulinResis-
tance Atherosclerosis Study (IRAS)
Investigators. Arterioscler Thromb Vasc
Biol 1997;17:64–71
4. Malmstrom R, Packard CJ, Caslake M,
Bedford D, Stewart P, Yki-Ja ¨rvinen H,
Shepherd J, Taskinen MR. Defective reg-
ulation of triglyceride metabolism by in-
sulin in the liver in NIDDM. Diabetologia
1997;40:454–462
5. Hopkins GJ, Barter PJ. Role of triglycer-
ide-rich lipoproteins and hepatic lipase in
determining the particle size and compo-
sition of high density lipoproteins. J Lipid
Res 1986;27:1265–1277
6. Berneis KK, Krauss RM. Metabolic origins
and clinical signiﬁcance of LDL heteroge-
neity. J Lipid Res 2002;43:1363–1379
7. Hokanson JE, Austin MA. Plasma triglyc-
eride level is a risk factor for cardiovascu-
lar disease independent of high-density
lipoprotein cholesterol level: a meta-anal-
ysis of population-based prospective
studies. J Cardiovasc Risk 1996;3:213–
219
8. Sarwar N, Danesh J, Eiriksdottir G, Sig-
urdsson G, Wareham N, Bingham S,
Boekholdt SM, Khaw KT, Gudnason V.
TriglyceridesandtheriskofCHD:10,158
incident cases among 262,525 partici-
pants in 29 Western prospective studies.
Circulation 2007;115:450–458
9. BansalS,BuringJE,RifaiN,MoraS,Sacks
FM, Ridker PM. Fasting compared with
nonfasting triglycerides and risk of car-
diovascular events in women. JAMA
2007;298:309–316
10. Nordestgaard BG, Benn M, Schnohr P,
Tybjaerg-Hansen A. Nonfasting triglycer-
ides and risk of myocardial infarction,
ischemic heart disease, and death in men
and women. JAMA 2007;98:299–308
11. GoldbourtU,YaariS,MedalieJH.Isolated
low HDL cholesterol as a risk factor for
coronary heart disease mortality: a 21-
year follow-up of 8000 mMen. Arterio-
sclerThrombVascBiol1997;17:107–113
12. Genest JJ, McNamara JR, Salem DN,
Schaefer EJ. Prevalence of risk factors in
men with premature coronary artery dis-
ease. Am J Cardiol 1991;67:1185–1199
13. Hausmann D, Johnson JA, Sudhir K,
Mullen WL, Friedrich G, Fitzgerald PJ,
Chou TM, Ports TA, Kane JP, Malloy MJ,
Yock PG. Angiographically silent ath-
erosclerosis detected by intravascular
ultrasound in patients with familial hy-
percholesterolemia and familial com-
bined hyperlipidemia: correlation with
high density lipoproteins. J Am Coll Car-
diol 1996;27:1562–1570
14. Baldassarre D, Amato M, Pustina L,
Tremoli E, Sirtori CR, Calabresi L,
Franceschini G. Increased carotid artery
intima–media thickness in subjects with
primaryhypoalphalipoproteinemia.Arte-
rioscler Thromb Vasc Biol 2002;22:317–
322
15. Johnsen SH, Mathiesen EB, Fosse E,
Joakimsen O, Stensland-Bugge E, Njøls-
tad I, Arnesen E. Elevated high-density
lipoprotein cholesterol levels are protec-
tive against plaque progression: a fol-
low-up study of 1952 persons with
carotid atherosclerosis: the Tromsø
Study. Circulation 2005;112:498–504
16. Van der Steeg WA, Holme I, Boekholdt
SM,LarsenML,LindahlC,StroesES,Tik-
kanen MJ, Wareham NJ, Faergeman O,
Olsson AG, Pedersen TR, Khaw KT,
Kastelein JJ. High-density lipoprotein
cholesterol, high-density lipoprotein par-
ticle size, and apolipoprotein A-I: signiﬁ-
cance for cardiovascular risk: the IDEAL
and EPIC-Norfolk studies. J Am Coll Car-
diol 2008;51:634–642
17. Colhoun HM, Betteridge DJ, Durrington
PN, Hitman GA, Neil HA, Livingstone SJ,
Thomason MJ, Mackness MI, Charlton-
Menys V, Fuller JH. CARDS investigators:
primary prevention of cardiovascular dis-
easewithatorvastatinintype2diabetesin
the Collaborative Atorvastatin Diabetes
Study (CARDS): multicentre randomised
placebo-controlled trial. Lancet 2004;
364:685–696
18. Deedwania P, Barter P, Carmena R Fru-
chartJC,GrundySM,HaffnerS,Kastelein
JJ, LaRosa JC, Schachner H, Shepherd J,
Waters DD. Treating to New Targets In-
vestigators: Reduction of low-density li-
poprotein cholesterol in patients with
coronaryheartdiseaseandmetabolicsyn-
drome: analysis of the Treating to New
Targetsstudy.Lancet2006;368:919–928
19. Barter P, Gotto AM, LaRosa JC, Maroni J,
Szarek M, Grundy SM, Kastelein JJ, Bitt-
ner V, Fruchart JC. Treating to New Tar-
gets Investigators: HDL cholesterol, very
low levels of LDL cholesterol, and cardio-
vascular events. N Engl J Med 2007;357:
1301–1310
20. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso
AW, Schoenhagen P, Hu T, Wolski K,
Crowe T, Desai MY, Hazen SL, Kapadia
SR, Nissen SE. Statins, high-density li-
poprotein cholesterol, and regression of
coronary atherosclerosis. JAMA 2007;
297:499–508
Triglycerides and HDL cholesterol
S376 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.org21. Miller M, Cannon CP, Murphy SA, Qin J,
RayKK,BraunwaldE.PROVEIT-TIMI22
Investigators: Impact of triglyceride levels
beyond low-density lipoprotein choles-
terolafteracutecoronarysyndromeinthe
PROVE IT-TIMI 22 Trial. J Am Coll Car-
diol 2008;51:724–730
22. Hogue JC, Lamarche B, Tremblay AJ,
BergeronJ,Gagne ´ C,CoutureP.Differen-
tial effect of atorvastatin and fenoﬁbrate
on plasma oxidized low-density lipopro-
tein, inﬂammation markers, and cell ad-
hesion molecules in patients with type 2
diabetes mellitus. Metabolism 2008;
57:380–386
23. Marx N, Sukhova GK, Collins T, Libby P,
Plutzky J. PPAR alpha activators inhibit
cytokine-induced vascular cell adhesion
molecule-1 expression in human endo-
thelial cells. Circulation 1999;22:3125–
3131
24. MarxN,KehrleB,KohlhammerK,Koenig
W, Hombach V, Libby P, Plutzky J. PPAR
activators as anti-inﬂammatory mediators
inhumanTlymphocytes:implicationsfor
atherosclerosis and transplantation-asso-
ciated arteriosclerosis. Circ Res 2002;90:
703–710
25. Vakkilainen J, Steiner G, Ansquer JC,
Aubin F, Rattier S, Foucher C, Hamsten
A, Taskinen MR. DAIS Group: Relation-
ships between low-density lipoprotein
particle size, plasma lipoproteins, and
progression of coronary artery disease:
the Diabetes Atherosclerosis Intervention
Study (DAIS). Circulation 2003;107:
1733–1737
26. Bloomﬁeld Rubins H, Robins SJ, Collins
D,NelsonDB,ElamMB,SchaeferEJ,Faas
FH, Anderson JW. Diabetes, plasma insu-
lin, and cardiovascular disease: subgroup
analysis from the Department of Veterans
Affairs High-Density Lipoprotein Inter-
vention Trial (VA-HIT). Arch Intern Med
2002;162:2597–2604
27. Manninen V, Tenkanen L, Koskinen P,
Huttunen JK, Ma ¨ntta ¨ri M, Heinonen OP,
Frick MH. Joint effects of serum triglycer-
ide and LDL cholesterol and HDL choles-
terol concentrations on coronary heart
disease risk in the Helsinki Heart Study:
implications for treatment. Circulation
1992;85:37–45
28. Tenenbaum A, Motro M, Fisman EZ,
Tanne D, Boyko V, Behar S. Bezaﬁbrate
for the secondary prevention of myocar-
dial infarction in patients with metabolic
syndrome. Arch Intern Med 2005;165:
1154–1160
29. FIELD Study Investigators. Effects of
long-term fenoﬁbrate therapy on cardio-
vascular events in 9795 people with type
2 diabetes mellitus (the FIELD study):
randomisedcontrolledtrial.Lancet2005;
366:1849–1861
30. Muhlestein JB, May HT, Jensen JR, Horne
BD, Lanman RB, Lavasani F, Wolfert RL,
Pearson RR, Yannicelli HD, Anderson JL.
The reduction of inﬂammatory biomark-
ers by statin, ﬁbrate, and combination
therapy among diabetic patients with
mixed dyslipidemia: The DIACOR (Dia-
betes and Combined Lipid Therapy Regi-
men) Study. J Am Coll Cardiol 2006;48:
396–401
31. Canner PL, Berge KG, Wenger NK, Stam-
ler J, Friedman L, Prineas RJ, Friedewald
W. Fifteen year mortality in Coronary
Drug Project patients: long-term beneﬁt
with niacin. J Am Coll Cardiol 1986;8:
1245–1255
32. Brown BG, Zhao XQ, Chait A, Fisher LD,
Cheung MC, Morse JS, Dowdy AA, Marino
EK, Bolson EL, Alaupovic P, Frohlich J, Al-
bers JJ. Simvastatin and niacin, antioxidant
vitamins, or the combination for the pre-
vention of coronary disease. N Engl J Med
2001;345:1583–1592
33. Taylor AJ, Sullenberger LE, Lee HJ, Lee
JK, Grace KA. Arterial Biology for the In-
vestigation of the Treatment Effects of Re-
ducing Cholesterol (ARBITER) 2: a
double-blind, placebo-controlled study
of extended-release niacin on atheroscle-
rosisprogressioninsecondaryprevention
patients treated with statins. Circulation
2004;110:3512–3517
34. Durrington PN, Bhatnager D, Mackness
MI, Morgan J, Julier K, Khan MA, France
M. An omega-3-polyunsaturated fatty
acid concentrate administered for one
yeardecreasedtriglyceridesinsimvastatin
treated patients with coronary heart dis-
ease and persisting hypertriglyceridae-
mia. Heart 2001;85:544–548
35. ChanDC,WattsGF,BarrettPH,BeilinLJ,
Redgrave TG, Mori TA. Regulatory effects
of HMG CoA reductase inhibitor and ﬁsh
oils on apolipoprotein B-100 kinetics in
insulin-resistant obese male subjects with
dyslipidemia. Diabetes 2002;51:2377–
2386
36. Chan DC, Watts GF, Nguyen MN, Bar-
rett PH. Factorial study of the effect of
n-3-fatty acid supplementation and
atorvastatin on the kinetics of HDL apo-
lipoproteins A-I and A-II in men with
abdominal obesity. Am J Clin Nutr
2006;84:37–43
37. Marchioli R, Barzi F, Bomba E Chieffo C,
DiGregorioD,DiMascioR,FranzosiMG,
GeraciE,LevantesiG,MaggioniAP,Man-
tini L, Marﬁsi RM, Mastrogiuseppe G,
Mininni N, Nicolosi GL, Santini M,
SchweigerC,TavazziL,TognoniG,Tucci
C, Valagussa F. GISSI-Prevenzione Inves-
tigators: Early protection against sudden
death by n-3 polyunsaturated fatty acids
after myocardial infarction: time course
analysis of the results of the Gruppo Ital-
iano per lo Studio della Sopravvivenza
nell’Infartio miocardico (GISSI)-Preven-
zione. Circulation 2002;105:1897–1903
38. Yokoyama M, Origasa H, Matsuzaki M,
MatsuzawaY,SaitoY,IshikawaY,Oikawa
S, Sasaki J, Hishida H, Itakura H, Kita T,
Kitabatake A, Nakaya N, Sakata T, Shi-
madaK,ShiratoK.JapanEPALipidInter-
vention Study (JELIS) Investigators:
Effects of eicosapentaenoic acid on major
coronaryeventsinhypercholesterolaemic
patients (JELIS): a randomized open-la-
bel, blinded endpoint analysis. Lancet
2007;369:1090–1098
39. GISSI-HF Investigators. Effect of n-3
polyunsaturated fatty acids in patients
with chronic heart failure (the GISSI-HF
trial): a randomised, double-blind, place-
bo-controlled trial. Lancet 2008;372:
1223–1230
40. Hooper L, Thompson RL, Harrison RA,
Summerbell CD, Ness AR, Moore HJ,
Worthington HV, Durrington PN, Hig-
gins JP, Capps NE, Riemersma RA, Ebra-
him SB, Davey Smith G. Risks and
beneﬁts of omega 3 fats for mortality, car-
diovascular disease, and cancer: system-
atic review. BMJ 2006;332:752–760
41. ORIGIN Trial Investigators. Rationale, de-
sign, and baseline characteristics for a large
international trial of cardiovascular disease
prevention in people with dysglycemia: the
ORIGINTrial(OutcomeReductionwithan
Initial Glargine Intervention). Am Heart J
2008;155:26–32
42. Barter PJ, Caulﬁeld M, Eriksson M,
Grundy SM, Kastelein JJ, Komajda M,
Lopez-Sendon J, Mosca L, Tardif JC, Wa-
ters DD, Shear CL, Revkin JH, Buhr KA,
Fisher MR, Tall AR, Brewer B. Effects of
torcetrapibinpatientsathighriskforcor-
onary events. N Engl J Med 2007;
357:2109–2122
43. Bloomﬁeld D, Carlson GL, Sapre A,
Tribble D, McKenney JM, Littlejohn TW
III, Sisk CM, Mitchel Y, Pasternak RC. Ef-
ﬁcacy and safety of the cholesteryl ester
transfer protein inhibitor anacetrapib as
monotherapy and coadministered with
atorvastatin in dyslipidemic patients. Am
Heart J 2009;157:352–360
44. Nissen SE, Tsunoda T, Tuzcu EM,
Schoenhagen P, Cooper CJ, Yasin M,
Eaton GM, Lauer MA, Sheldon WS,
Grines CL, Halpern S, Crowe T, Blanken-
ship JC, Kerensky R. Effect of recombi-
nant ApoA-I milano on coronary
atherosclerosis in patients with acute cor-
onary syndromes: a randomized con-
trolled trial. JAMA 2003;290:2292–2300
45. Navab M, Anantharamaiah GM, Reddy
ST, Hama S, Hough G, Grijalva VR, Yu N,
AnsellBJ,DattaG,GarberDW,Fogelman
AM. Apolipoprotein A-I mimetic pep-
tides. Arterioscler Thromb Vasc Biol
2005;25:1325–1331
46. Anderson T, Charbonneau F, Chan S,
Lonn E. The effect of large unilamellar
vesicles on vascular function in patients
with coronary atherosclerosis. Athero-
sclerosis 2008;200:424–431
47. Scott J. The liver X receptor and athero-
sclerosis. N Engl J Med 2007;357:2195–
2197
Bitzur and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 S377